On March 20, 2026, Novo Nordisk’s Indian patent on semaglutide expired. Within 48 hours, more than sixteen generic versions of Ozempic had landed on Indian pharmacy shelves. Prices crashed 70 to 90%. Zydus launched three brands and anchored supply for Lupin and Torrent. Sun Pharma, Alkem and Natco piled in behind.

Dr. Reddy’s launched Obeda with plans for 87 countries. Torrent went oral — the first Indian company to offer a generic tablet alongside an injectable, giving physicians the choice between needle and pill for the same molecule.

India had, in two days, demonstrated something it does better than any country on earth: copy any drug. For thirty years, the world’s most capable copying machine has been trying, fitfully, to do something harder — invent a novel drug for global markets.

Several Indian companies are now running original-drug programmes of genuine global ambition. Zydus has an oral drug for kidney anaemia already approved in India and China, and an NLRP3 inflammasome inhibitor for ALS on the USFDA Fast Track. Aurigene, Dr. Reddy’s drug-discovery subsidiary, has been running oncology programmes for two decades.

But it is in obesity, the disease that semaglutide just made the most contested space in global pharma, that Indian pharma’s innovation is most sharply visible.

Mankind Pharma has invented MKP10241 at its Gurugram research centre, secured patents through to 2037, and is testing it in mid-stage trials in Australia. MKP10241 targets GPR119, a receptor that drives insulin and GLP-1 secretion; because it is a small molecule rather than a peptide, it can be formulated as a tablet. If it works, it will be the first obesity treatment anywhere that comes as a pill rather than an injection.

Sun Pharma has its own candidate: Utreglutide, a GLP-1 peptide agonist that in early trials cut blood-fat levels alongside weight — a profile distinct enough that the company is seeking a Western partner to fund Phase 3. Zydus is running the most advanced original-drug programme in Indian pharma history.

These bets are unfolding inside an industry that has never needed to make them. For thirty years, copying was more profitable than inventing — faster, cheaper, almost guaranteed to succeed.

The semaglutide rush is that logic at its fiercest: sixteen generics in 48 hours, prices gone. Every patent that expires draws fifty brands, and margins collapse in this crowded business within weeks. The comfortable returns that funded three decades of growth are thinner, and getting thinner still.

A generics company, however large, earns nothing on molecules it did not discover. The originator’s premium — the royalties, the licensing income, the durable pricing power — flows elsewhere. A growing number of Indian pharma companies are now asking whether that has to be permanent.

The Scale Of What Exists

India supplies 40% of America’s generic medicines and two-thirds of the world’s vaccines. Its exports reached Rs 2.60 lakh crore in FY25; total industry turnover, including domestic sales, was Rs 4.72 lakh crore. The sector is not short of scale or ambition. The problem is direction.

India’s drug companies have built their R&D operations around improving and extending medicines that already exist. Yusuf Hamied, the Cipla chairman who made AIDS drugs affordable for millions, was candid about this in a 2015 interview with The Lancet: “Our R&D at Cipla is targeted at incremental innovation — how to change and improve a product that already exists.” The figure below shows what that looks like in numbers.

The Template That Failed

The odds against inventing are brutal. A new drug takes ten to fifteen years, costs $1–2 billion, and fails nine times out of ten. The person who understood this most clearly and chose to try anyway was Kallam Anji Reddy. He built India’s first drug discovery programme in 1993 alongside the generics business that was making him rich.

The generics side worked spectacularly: Dr. Reddy’s became the first Indian company to file for US drug approval, and in 2001 earned Rs 366 crore in FY2002 from its 180-day exclusivity on a generic fluoxetine 40mg capsule.

The original-drug side did not. Between 1997 and 2001, Dr. Reddy’s out-licensed three diabetes molecules to Novo Nordisk and Novartis. All three were abandoned after disappointing clinical results. Drug discovery remained, in Anji Reddy’s own words, his “unfinished agenda.”

The subsidiary Aurigene has been running drug-discovery programmes for two decades, generating molecules that Debiopharm and others have paid to develop — a contract discovery model, not quite the same as owning a drug. The dream is thirty years old.

How Close Is India, Actually

The current generation of Indian drug programmes is the most serious since Dr. Reddy’s was licensing molecules to Novo Nordisk in the 1990s. Of the three obesity candidates, Zydus is furthest along.

Saroglitazar was invented in Ahmedabad, approved in India in 2013 and has been on the Indian market for over a decade. That approval counts for nothing at the USFDA, which requires its own trials on its own evidentiary standards. Zydus has been running those since scratch — Phase IIb/III — with an NDA filing scheduled for Q4 FY26, twenty-five years after the molecule was first discovered in Ahmedabad. Utreglutide is a step behind. MKP10241 is earlier still, but potentially the most consequential: a pill-form obesity drug would be a global first.

What It Will Actually Take

Patient capital. Inventing drugs requires investors willing to wait a decade and absorb repeated failure. India’s investment community largely is not. Biotech funding flows toward diagnostics, health apps, and medical devices.

Zydus and Mankind have funded drug discovery out of generics profits. Sun is asking a Western partner to pay for the expensive part. None of these is a sustainable model for building a discovery industry at scale.

A shared discovery institution. India’s top ten listed pharmaceutical companies together generate well over Rs 1.5 lakh crore in annual revenue. Individually, none of them is large enough to sustain a first-in-class drug pipeline from discovery through Phase 3.

Collectively, they could be. An industry-funded research organisation — on the model of the Wellcome Sanger Institute, or the early Merck Institute for Therapeutic Research — that pools scientific talent, shares early-stage risk and feeds development candidates to member companies is not a fantasy. It is a deliberate choice that Indian pharma has not yet made.

Trials built for Western regulators. USFDA does not treat foreign regulatory approvals as a substitute for its own evidentiary requirements. Saroglitazar was approved in India in 2013, but Zydus still had to run a full separate US trial programme from scratch. A drug company that designs its trials to the USFDA standard from day one, even if the work is done in India, gets to the finish line faster.

A bridge from university to industry. CSIR-CDRI in Lucknow has contributed to 14 DCGI-approved drugs. The IITs publish serious medicinal chemistry research. What India’s universities have not reliably produced is a compound ready for industry to pick up and test in humans — the IND-ready package that closes the gap between bench and first human dose. That valley of death remains the structural weakness no government programme has yet fixed.

China and the Road Not Taken

The comparison that should unsettle India is not with Pfizer or Roche. It is with China. Twenty years ago, the two countries were at roughly the same point: large generic manufacturing bases, almost no original drugs, dependent on Western patents. China then decided to change this.

It reformed its drug regulator in 2016. It invested at a scale India has not matched — sixteen-fold more on R&D as a share of the economy — and produced results: original drug approvals rose from 11 in 2019 to 46 in 2024.

BeiGene’s cancer drug zanubrutinib was approved simultaneously in the US and China. Morgan Stanley projects that Chinese-invented drugs could account for 35% of US approvals by 2040. China is now the country Western pharma licences from, paying for molecules that Chinese scientists invented. India remains the country they license through: a manufacturer, a distributor, a route to market, but not yet the origin of the drug."

The semaglutide gold rush will improve Indian pharma’s balance sheets. It will not change the structural position. What could change it is a readout from an Australian trial site, a US regulatory filing from Ahmedabad, or a licensing deal that takes an Indian-invented molecule into Western clinical testing.

Saroglitazar, Utreglutide, MKP10241 are three molecules, three mechanisms, all chasing the same prize in the same week their industry demonstrated it can copy the world’s most valuable drug in 48 hours. India has always known how to make any drug. It is learning, slowly and at considerable expense, whether it can invent a global-scale one.